Core Insights - Climb Bio Inc. (NASDAQ:CLYM) is identified as a promising biotech penny stock, with analysts projecting a price target increase from $9 to $11 while maintaining a Buy rating due to anticipated data readouts in 2026 for its lead asset Budoprutug [1][2] Group 1: Company Overview - Climb Bio is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases, primarily through its two main assets: Budoprutug and CLYM116 [2][5] - Budoprutug is an anti-CD19 antibody targeting B-cell mediated diseases, while CLYM116 is an anti-APRIL antibody aimed at treating IgA nephropathy [2] Group 2: Clinical Trials and Data Readouts - The company has initiated the PrisMN Phase 2 trial for Budoprutug in Primary Membranous Nephropathy, with the trial designed to evaluate safety, pharmacokinetics, and preliminary efficacy, aiming for data release in 2026 [3] - A Phase 1 trial for a subcutaneous formulation of Budoprutug is currently ongoing, with initial data expected in the first half of 2026 [3] - Climb Bio is also conducting an open-label Phase 1b/2a trial for Budoprutug in patients with Immune Thrombocytopenia and a Phase 1b trial in Systemic Lupus Erythematosus patients, with preliminary efficacy results anticipated in the second half of 2026 [4]
H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks